An end-to-end integration is not a cautious pilot — it is a platform lock. By routing workforce upskilling, discovery analytics, manufacturing optimization, and commercial operations through a single vendor, Novo Nordisk surrenders the optionality that a modular, multi-vendor approach would preserve. The partnership's late-2026 scaled deployment target means the organizational muscle memory for OpenAI's tooling will be built before the next generation of competing models has time to prove itself at clinical scale. That timeline is a deliberate structural choice, not an administrative detail — and it is the choice…